AIVIS (CEO Daehong Lee), an AI-based digital pathology solutions company, announced on the 23rd that it had won an Excellence Award at the 2025 K-Digital Grand Championship. Hosted by the Ministry of Science and ICT and organized by the National IT Industry Promotion Agency (NIPA), the competition is a government-sponsored event that seeks to discover companies with innovative AI and data-based technologies. This year, the top seven teams participated in the finals, with AIVIS being the only one to make it into the medical AI category.
With this award, Avis secured a cash prize of 20 million won and other benefits, including opportunities to participate in government-funded projects and attract investment next year. In the final round, Avis presented its improved cancer diagnosis accuracy and clinical application cases utilizing its core solution, "Qanti® IHC," receiving high praise from the judges.
Quanti IHC provides AI-based quantitative analysis capabilities to improve diagnostic variability among pathologists and the complexity of biomarker interpretation. The solution, which received MFDS approval in September of last year, has seen rapid growth, being adopted by 12 major general hospitals in Korea within a year of its launch. Hospitals adopting the solution can secure the basis for billing for pathology morphometry, thereby achieving both clinical utility and business value.
Avis's technological prowess has also been proven on the international stage. At ESMO Asia 2025 in Singapore last December, the "Quanti Breast HER2" AI platform was used to validate the diagnostic performance of HER2 in 168 breast cancer patients at Samsung Medical Center. The results showed that using the AI, the Fleiss kappa coefficient between pathologists increased from 0.5181 to 0.7232, significantly improving diagnostic accuracy.
Avis is also pursuing global expansion. It is collaborating with AstraZeneca Korea on a project to improve the diagnostic environment for HER2-low-expressing breast cancer and is building partnerships with global pathology equipment companies such as Philips, Roche, and Leica. Avis is conducting proof-of-concept trials at approximately 20 major hospitals in Asia, exploring the potential of entering overseas markets.
Lee Dae-hong, CEO of Avis, said, “This award demonstrates that pathology AI creates real value in clinical and industrial settings,” and added, “We will improve the quality of cancer treatment with accurate and consistent diagnostic technology and leap forward as a platform company that leads the global cancer diagnosis standard.”
- See more related articles
You must be logged in to post a comment.